Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | CHIEF FINANCIAL OFFICER | September 17, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,000 |
Last balance in matching sequence
After 2026-09-17 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-09-17 · Exercise / conversion · Acquired 3,982 · Balance 44,018 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 2 · 2026-09-17 · Sale · Disposed 3,535 · Balance 40,483 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 3 · 2026-09-17 · Sale · Disposed 2,194 · Balance 38,289 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Row 4 · 2026-09-17 · Sale · Disposed 289 · Balance 38,000 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2034-02-13 | Direct | 181,018 |
Reported balance
After 2026-09-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-17 · Exercise / conversion · Disposed 3,982 · Balance 181,018 F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2025 Filed Apr 30, 2025 22:59 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-25-011596 · form4-04302025_100450.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 23:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-009301 · form4-03312025_110331.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,556 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 23:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $21.33 | $69,320.88 |
DisclosureSEC source: 0001415889-25-009301 · form4-03312025_110331.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.75 to $21.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 23:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-25-009301 · form4-03312025_110331.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 23:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-009066 · form4-03262025_110349.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,806 Underlying: Common Stock · 1,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 23:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,000 | $22.50 | $22,504.50 |
DisclosureSEC source: 0001415889-25-009066 · form4-03262025_110349.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.50 to $22.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 23:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,000 | $2.48 | $2,480.00 |
DisclosureSEC source: 0001415889-25-009066 · form4-03262025_110349.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 23:02 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-007286 · form4-03062025_110331.xml · derivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,806 Underlying: Common Stock · 10,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 23:02 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 10,000 | $2.48 | $24,800.00 |
DisclosureSEC source: 0001415889-25-007286 · form4-03062025_110331.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:07 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-006296 · form4-03042025_010306.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,806 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:07 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $20.41 | $66,326.98 |
DisclosureSEC source: 0001415889-25-006296 · form4-03042025_010306.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.98 to $20.8818. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 01:07 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-25-006296 · form4-03042025_010306.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 22:27 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 171,000 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003511 · form4-02102025_100207.xml · derivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,000 Underlying: Common Stock · 171,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 00:06 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-003405 · form4-02082025_120242.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,056 Underlying: Common Stock · 1,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 00:06 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,000 | $22.52 | $22,524.40 |
DisclosureSEC source: 0001415889-25-003405 · form4-02082025_120242.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.50 to $22.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 05, 2025 Filed Feb 8, 2025 00:06 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,000 | $2.48 | $2,480.00 |
DisclosureSEC source: 0001415889-25-003405 · form4-02082025_120242.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| January 27, 2025 Filed Jan 30, 2025 00:21 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-002298 · form4-01302025_120123.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,056 Underlying: Common Stock · 3,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 27, 2025 Filed Jan 30, 2025 00:21 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,250 | $21.59 | $70,177.90 |
DisclosureSEC source: 0001415889-25-002298 · form4-01302025_120123.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.14 to $22.135. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 27, 2025 Filed Jan 30, 2025 00:21 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,250 | $2.48 | $8,060.00 |
DisclosureSEC source: 0001415889-25-002298 · form4-01302025_120123.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-001007 · form4-01072025_090141.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,306 Underlying: Common Stock · 1,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The 1,000 share option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. F5 · balance_after: The number of derivative securities beneficially owned following the option exercise is as of January 3, 2025 and reflects the option exercise that occurred December 13, 2024, and reported herein, and subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,000 | $25.04 | $25,038.60 |
DisclosureSEC source: 0001415889-25-001007 · form4-01072025_090141.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 F1 · kind: The 1,000 share option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.045. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,000 | $2.48 | $2,480.00 |
DisclosureSEC source: 0001415889-25-001007 · form4-01072025_090141.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The 1,000 share option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 900 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-030323 · form4-12312024_101209.xml · derivative · entry 6 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,306 Underlying: Common Stock · 900 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 900 | $22.51 | $20,255.49 |
DisclosureSEC source: 0001415889-24-030323 · form4-12312024_101209.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.50 to $22.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 900 | $2.48 | $2,232.00 |
DisclosureSEC source: 0001415889-24-030323 · form4-12312024_101209.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 3,350 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-030323 · form4-12312024_101209.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,206 Underlying: Common Stock · 3,350 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,350 | $22.15 | $74,218.92 |
DisclosureSEC source: 0001415889-24-030323 · form4-12312024_101209.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.58 to $22.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 3,350 | $2.48 | $8,308.00 |
DisclosureSEC source: 0001415889-24-030323 · form4-12312024_101209.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| December 13, 2024 Filed Jan 7, 2025 21:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-001007 · form4-01072025_090141.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,556 Underlying: Common Stock · 13,000 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. F4 · balance_after: The number of derivative securities beneficially owned following the option exercise was as of December 13, 2024 and does not reflect subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024. Read SEC document |
| December 13, 2024 Filed Jan 7, 2025 21:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 13,000 | $2.48 | $32,240.00 |
DisclosureSEC source: 0001415889-25-001007 · form4-01072025_090141.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-028001 · form4-12022024_101235.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,556 Underlying: Common Stock · 5,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,000 | $25.38 | $25,375.50 |
DisclosureSEC source: 0001415889-24-028001 · form4-12022024_101235.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $25.26 to $25.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,250 | $24.78 | $105,312.88 |
DisclosureSEC source: 0001415889-24-028001 · form4-12022024_101235.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.25 to $25.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 22:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 5,250 | $2.48 | $13,020.00 |
DisclosureSEC source: 0001415889-24-028001 · form4-12022024_101235.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 22:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-025779 · form4-10302024_101039.xml · derivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,806 Underlying: Common Stock · 6,250 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 22:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 650 | $29.11 | $18,922.15 |
DisclosureSEC source: 0001415889-24-025779 · form4-10302024_101039.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $28.97 to $29.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 22:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,600 | $28.49 | $159,562.48 |
DisclosureSEC source: 0001415889-24-025779 · form4-10302024_101039.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 650 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.97 to $28.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 22:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 6,250 | $2.48 | $15,500.00 |
DisclosureSEC source: 0001415889-24-025779 · form4-10302024_101039.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:19 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 814 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-025501 · form4-10222024_081055.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,056 Underlying: Common Stock · 814 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:19 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 814 | $30.00 | $24,422.44 |
DisclosureSEC source: 0001415889-24-025501 · form4-10222024_081055.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:19 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 814 | $2.48 | $2,018.72 |
DisclosureSEC source: 0001415889-24-025501 · form4-10222024_081055.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 22:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 1,270 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-024900 · form4-10082024_101002.xml · derivative · entry 6 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,870 Underlying: Common Stock · 1,270 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 22:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $27.51 | $34,935.29 |
DisclosureSEC source: 0001415889-24-024900 · form4-10082024_101002.xml · nonDerivative · entry 4 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 22:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,270 | $2.48 | $3,149.60 |
DisclosureSEC source: 0001415889-24-024900 · form4-10082024_101002.xml · nonDerivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 22:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 10,218 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-024900 · form4-10082024_101002.xml · derivative · entry 5 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,140 Underlying: Common Stock · 10,218 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F4 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 22:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 10,218 | $27.51 | $281,078.79 |
DisclosureSEC source: 0001415889-24-024900 · form4-10082024_101002.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 22:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 10,218 | $2.48 | $25,340.64 |
DisclosureSEC source: 0001415889-24-024900 · form4-10082024_101002.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 22:44 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 521 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-024669 · form4-10032024_101051.xml · derivative · entry 3 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,358 Underlying: Common Stock · 521 shares Expires 2031-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F3 · derivative.exercise_date: The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 22:44 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 521 | $27.54 | $14,346.88 |
DisclosureSEC source: 0001415889-24-024669 · form4-10032024_101051.xml · nonDerivative · entry 2 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.52 to $27.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 22:44 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 521 | $2.48 | $1,292.08 |
DisclosureSEC source: 0001415889-24-024669 · form4-10032024_101051.xml · nonDerivative · entry 1 Hohl Benjamin · CIK 0001882764 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.